Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups.
The last earnings update was 40 days ago.
Discounted Cash Flow Calculation for ENXTPA:ALONC using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
Oncodesign Société Anonyme
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
ENXTPA:ALONC DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
Oncodesign Société Anonyme
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
Oncodesign Société Anonyme
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Oncodesign Société Anonyme's share price is below the future cash flow value, and at a moderate discount (> 20%).
Oncodesign Société Anonyme's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Oncodesign Société Anonyme's
is considered below, and whether this is a fair price.
Price based on past earnings
Oncodesign Société Anonyme's earnings available for a low price, and how does
this compare to other companies in the same industry?
Oncodesign Société Anonyme's earnings are expected to grow significantly at over 20% yearly.
Oncodesign Société Anonyme's revenue is expected to grow by 12% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Oncodesign Société Anonyme's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Oncodesign Société Anonyme
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Oncodesign Société Anonyme's finances.
The net worth of a company is the difference between its assets and liabilities.
Oncodesign Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Oncodesign Société Anonyme's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Oncodesign Société Anonyme's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 1.8x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Does Oncodesign Société Anonyme's (EPA:ALONC) CEO Pay Compare Well With Peers?
Philippe Genne has been the CEO of Oncodesign Société Anonyme (EPA:ALONC) since 2010. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Philippe Genne's Compensation Compare With Similar Sized Companies?
Is Oncodesign Société Anonyme's (EPA:ALONC) CEO Paid At A Competitive Rate?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Philippe Genne's Compensation Compare With Similar Sized Companies. … Our data indicates that Oncodesign Société Anonyme is worth €61m, and total annual CEO compensation is €204k.
Is Oncodesign Société Anonyme's (EPA:ALONC) CEO Paid Enough Relative To Peers?
Philippe Genne took the helm as Oncodesign Société Anonyme's (EPA:ALONC) CEO and grew market cap to €65.97m recently. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … Check out our latest analysis for Oncodesign Société Anonyme
Should You Sell Oncodesign Société Anonyme (EPA:ALONC) At This PE Ratio?
Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for ALONC Price per share = €9.82 Earnings per share = €0.076 ∴ Price-Earnings Ratio = €9.82 ÷ €0.076 = 128.4x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … For example, if you accidentally compared lower growth firms with ALONC, then ALONC’s P/E would naturally be higher since investors would reward ALONC’s higher growth with a higher price. … Alternatively, if you inadvertently compared riskier firms with ALONC, ALONC’s P/E would again be higher since investors would reward ALONC’s lower risk with a higher price as well.
Oncodesign Société Anonyme, a biotechnology company, conducts research and development work on new therapeutic and diagnostic tools along with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services for proof of concept stage; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company is also involved in the analysis of new chemical and biological entities, and membrane proteins; and immune analysis and monitoring, and microbiological monitoring. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company was founded in 1995 and is headquartered in Dijon, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.